The estimated Net Worth of Richard Afable is at least $68.4 Tysiąc dollars as of 23 June 2014. Richard Afable owns over 1,000 units of Acelrx Pharmaceuticals Inc stock worth over $860 and over the last 11 years he sold ACRX stock worth over $0. In addition, he makes $67,504 as Independent Director at Acelrx Pharmaceuticals Inc.
Richard has made over 1 trades of the Acelrx Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of ACRX stock worth $10,300 on 23 June 2014.
The largest trade he's ever made was buying 1,000 units of Acelrx Pharmaceuticals Inc stock on 23 June 2014 worth over $10,300. On average, Richard trades about 83 units every 0 days since 2013. As of 23 June 2014 he still owns at least 1,000 units of Acelrx Pharmaceuticals Inc stock.
You can see the complete history of Richard Afable stock trades at the bottom of the page.
Dr. Richard F. Afable M.D. serves as Independent Director of the Company. Dr. Afable has served as Chief Executive Officer of Concierge Key Health, LLC since August 2018. Dr. Afable has served as trustee of Chapman University since March 2017, of Providence St. Joseph Health since January 2018, and he is the immediate past chair of the California Hospital Association. From July 2016 through December 2017, Dr. Afable has served as Executive Vice President and Chief Executive, Southern California, for Providence St. Joseph Health. From February 2013 to July 2016, Dr. Afable served as the Chief Executive Officer of Covenant Health Network, based in Irvine, California, a non-profit healthcare delivery system formed through the affiliation of Hoag Memorial Hospital Presbyterian and St. Joseph Health System. Prior to Covenant Health Network, Dr. Afable served as the President and Chief Executive of Hoag Memorial Hospital Presbyterian from 2005 to 2013. Prior to Hoag Memorial Hospital Presbyterian, Dr. Afable served as the Chief Medical Officer of Catholic Health East from 1999 to 2005. He earned a B.S. in biology, an M.D. degree from Loyola University of Chicago, and a Master’s in Public Health from the University of Illinois at Chicago. Dr. Afable’s scientific, financial and business expertise, including his experience as an executive officer in the health care industry, provides him with the qualifications and skills to serve as a director.
As the Independent Director of Acelrx Pharmaceuticals Inc, the total compensation of Richard Afable at Acelrx Pharmaceuticals Inc is $67,504. There are 12 executives at Acelrx Pharmaceuticals Inc getting paid more, with Vincent Angotti having the highest compensation of $2,125,050.
Richard Afable is 66, he's been the Independent Director of Acelrx Pharmaceuticals Inc since 2013. There are 2 older and 11 younger executives at Acelrx Pharmaceuticals Inc. The oldest executive at Acelrx Pharmaceuticals Inc is Lawrence G. Hamel, 69, who is the Consultant.
Richard's mailing address filed with the SEC is 3345 Michelson Dr #100, Irvine, CA 92612, USA.
Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over $25,363,406 worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth $26,783,172 . The most active insiders traders include Advisors Llcperceptive Life..., Advisors Llcedelman Josephp... oraz Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $109,939. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth $7,300.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: